Pathstone Holdings LLC Lowers Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

Pathstone Holdings LLC trimmed its stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 24.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,778 shares of the company's stock after selling 5,460 shares during the quarter. Pathstone Holdings LLC's holdings in HealthEquity were worth $1,373,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Truist Financial Corp grew its holdings in HealthEquity by 7.0% during the second quarter. Truist Financial Corp now owns 2,864 shares of the company's stock valued at $247,000 after purchasing an additional 188 shares during the period. Nisa Investment Advisors LLC increased its holdings in HealthEquity by 7.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,854 shares of the company's stock worth $246,000 after acquiring an additional 198 shares during the last quarter. Elk River Wealth Management LLC raised its stake in HealthEquity by 0.3% in the 3rd quarter. Elk River Wealth Management LLC now owns 66,181 shares of the company's stock valued at $5,417,000 after acquiring an additional 217 shares during the period. CWM LLC lifted its holdings in HealthEquity by 6.9% during the second quarter. CWM LLC now owns 3,958 shares of the company's stock valued at $341,000 after purchasing an additional 255 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its position in HealthEquity by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 13,314 shares of the company's stock worth $1,090,000 after purchasing an additional 303 shares during the period. 99.55% of the stock is owned by institutional investors.

Insider Activity at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the company's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the transaction, the director now owns 54,719 shares of the company's stock, valued at $4,540,582.62. This represents a 13.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Frank Corvino sold 1,039 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total value of $99,847.90. Following the completion of the sale, the director now owns 3,784 shares of the company's stock, valued at approximately $363,642.40. This trade represents a 21.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock worth $884,517 in the last three months. 2.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. JMP Securities restated a "market outperform" rating and set a $105.00 price target on shares of HealthEquity in a research note on Wednesday, September 4th. The Goldman Sachs Group initiated coverage on HealthEquity in a report on Friday, November 15th. They issued a "neutral" rating and a $108.00 price target for the company. Bank of America increased their price objective on HealthEquity from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Royal Bank of Canada reissued an "outperform" rating and issued a $92.00 price target on shares of HealthEquity in a report on Wednesday, September 4th. Finally, Barrington Research restated an "outperform" rating and issued a $105.00 price objective on shares of HealthEquity in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $107.23.

HealthEquity Price Performance

Shares of NASDAQ HQY traded down $0.93 during trading hours on Friday, reaching $101.54. 452,817 shares of the stock traded hands, compared to its average volume of 625,647. HealthEquity, Inc. has a 52-week low of $62.10 and a 52-week high of $105.82. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. The company's 50-day simple moving average is $89.72 and its two-hundred day simple moving average is $82.60. The company has a market capitalization of $8.87 billion, a P/E ratio of 85.39, a price-to-earnings-growth ratio of 1.60 and a beta of 0.52.

HealthEquity (NASDAQ:HQY - Get Free Report) last released its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The company had revenue of $299.93 million during the quarter, compared to analyst estimates of $284.48 million. Equities research analysts forecast that HealthEquity, Inc. will post 2.27 EPS for the current year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.